OBJECTIVE: To describe the prevalence of ZIKV exposure and positive test results in two different patient populations within a single urban institution in Texas. STUDY DESIGN: Between January 2015 and July 2017, two clinics at two separate hospitals were developed at our institution to serve as referral sources for women with ZIKV exposure during pregnancy. Aggregate demographics of the pregnant women receiving prenatal care at the two hospitals (hospitals A and B) were collected using a combined institutional delivery database. Laboratory evidence of ZIKV included positive NAT and/or IgM testing in maternal, placental or infant sample. Patient characteristics, ZIKV test results, delivery and infant outcomes were reported. Standard statistical analysis was performed. RESULTS: A total of 639 women were tested for ZIKV at our institution between January 2015 to July 2017 (hospital A 359, hospital B 280), comprising 4% of our total delivery volume. Demographic data for the two hospitals are displayed in table 1. Four (1.1%) patients from Hospital A and 32 (11.4%) patients from Hospital B tested positive for ZIKV (P<0.01) (see table 2). Of women delivered to date, no cases of congenital ZIKV were diagnosed in patients from Hospital A versus 3 (1.0%) cases in patients from Hospital B (p<0.05). CONCLUSION: Significant differences exist in the prevalence of ZIKV between two hospitals within the same geographic area. These differences should be considered in the testing recommendations for ZIKV during pregnancy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.